Collectively, our results strongly suggest the FFAR2 signal might antagonize TLR2- and TLR3-induced lung cancer progression via suppression of the cAMP-AMPK-TAK1 signaling axis for the activation of NF-κB. Here, FFAR2 is linked to lung carcinoma.